News & Updates

Show Multimedia Only
BPaLM regimen continues to show benefit against rifampicin-resistant tuberculosis

BPaLM regimen continues to show benefit against rifampicin-resistant tuberculosis

12 Dec 2023 byJairia Dela Cruz

In the treatment of patients with rifampicin-resistant tuberculosis, a 6-month oral regimen consisting of bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaLM) is safe and efficacious and compares favourably with standard of care, as shown in the final data from the phase IIB-III TB-PRACTECAL study.

12 Dec 2023
One in six CYPs in SG develop long COVID

One in six CYPs in SG develop long COVID

11 Dec 2023 byAudrey Abella

In Singapore, about one in six children and young persons (CYPs) developed long COVID, with persistence of ≥1 symptoms 3 months after an acute COVID-19 infection, a survey study suggests.

11 Dec 2023